RecruitingPhase 1NCT07691606

A Study of ARC-02 in B-cell NHL

A Study to Evaluate Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity of ARC-02 in Adult Participants With B-cell Non-Hodgkins Lymphoma (NHL)

Sponsor

Taiho Oncology, Inc.

Enrollment

140 participants

Start Date

Jun 22, 2026

Study Type

INTERVENTIONAL

Conditions

B-cell Non Hodgkin Lymphoma

Summary

This study is to assess safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary efficacy of ARC-02.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called ARC-02 and a drug called Rituximab for people with b-cell non hodgkin lymphoma. The study is currently recruiting participants at 29 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGARC-02

Intravenous (IV) infusion.

DRUGRituximab

IV infusion.

Locations(29)

Start Cala

Los Angeles, California, United States

Norton Cancer Institute

Louisville, Kentucky, United States

NYU Langone

New York, New York, United States

Levine Cancer Institute

Charlotte, North Carolina, United States

Massey Cancer Center

Richmond, Virginia, United States

Summit Cancer Centers - North Spokane

Spokane, Washington, United States

Froedtert & Medical College of Wisconsin

Milwaukee, Wisconsin, United States

Monash Health

Clayton, Australia

Austin Health

Melbourne, Australia

Linear Clinical Research

Nedlands, Australia

Gold Coast Hospital

Southport, Australia

Hopital Henri-Mondor

Créteil, France

Centre Hospitalier Universitaire de Lille (CHU Lille) - Hopital Claude Huriez

Lille, France

Hôpital Lyon Sud

Lyon, France

CHU Nantes - Hotel Dieu

Nantes, France

Institut Gustave Roussy

Villejuif, France

Centro di Riferimento Oncologico (CRO Aviano)

Aviano, Italy

ASST Papa Giovanni XXIII

Bergamo, Italy

University of Bologna

Bologna, Italy

Istituto Clinico Humanitas

Rozzano, Italy

Pratia Onkologia Katowice

Katowice, Poland

Pratia MCM Krakow

Krakow, Poland

Szpital AidPort

Skorzewo, Poland

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy

Warsaw, Poland

Hospital Universitari Vall d'Hebron

Barcelona, Spain

Hospital General San Pedro De Alcantara

Cáceres, Spain

The START Center for Cancer Care - Madrid (Fundacion Jimenez Diaz)

Madrid, Spain

START Madrid - Hospital Universitario Madrid Sanchinarro

Madrid, Spain

Hospital Universitario Virgen del Rocio

Seville, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07691606

Related Trials

IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas

NCT0536565913 locations

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

NCT0656403864 locations

Salvage Treatment With Glofitamab in R/R B-NHL: a GIMEMA-FIL Study

NCT059275581 location

A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies

NCT072206166 locations

A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

NCT0712345422 locations